MAB Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Mabion (WSE: MAB)
›
Mabion (WSE: MAB) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 199 employees.
The shares were at 9.400 PLN on 19 November 2026, up 15.3% over 52 weeks. Its 52-week range is 6.700 PLN to 11.22 PLN: the price is 16.2% below the high and 40.3% above the low.
Its market capitalisation is 151.93M PLN.
Mabion reports return on equity of -128.2%, an operating margin of -223.5% and revenue down 26.7% year over year.
Its debt exceeds its cash by 15.63M PLN, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.